Cartesian Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	160.32	212.61	76.91	106.44	4.74
Short-Term Investments	-	-	-	28.16	-
Cash & Short-Term Investments	160.32	212.61	76.91	134.6	4.74
Cash Growth	83.80%	176.44%	-42.86%	2742.70%	-
Accounts Receivable	0.35	0.87	8.85	9.76	3.13
Other Receivables	-	-	-	-	0.23
Receivables	0.35	0.87	8.85	9.76	3.35
Prepaid Expenses	2.72	3.14	4.97	3.49	0.05
Restricted Cash	-	-	-	0.29	-
Total Current Assets	163.4	216.63	90.73	148.14	8.14
Property, Plant & Equipment	17.45	15.45	12.18	14.41	1.5
Long-Term Investments	2	2	2	2	-
Goodwill	48.16	48.16	48.16	-	-
Other Intangible Assets	150.6	150.6	150.6	-	-
Other Long-Term Assets	7.29	2.19	1.38	1.34	0.03
Total Assets	388.89	435.02	305.05	165.89	9.67
Accounts Payable	0.45	0.29	3.15	0.32	-
Accrued Expenses	7.32	11.29	14.61	14.08	0.79
Current Portion of Long-Term Debt	-	-	-	8.48	-
Current Portion of Leases	3.79	2.85	2.17	1.61	0.17
Current Unearned Revenue	-	-	2.31	0.59	0.12
Other Current Liabilities	0.69	8.54	45.98	-	0.19
Total Current Liabilities	12.26	22.98	68.21	25.08	1.27
Long-Term Debt	-	-	-	17.79	-
Long-Term Leases	9.56	11.13	8.79	10.06	1.11
Long-Term Unearned Revenue	-	-	3.54	-	-
Long-Term Deferred Tax Liabilities	16.14	16.14	15.85	-	-
Other Long-Term Liabilities	353.46	391.58	348.29	19.14	0.35
Total Liabilities	391.42	441.83	444.68	72.06	2.72
Common Stock	0	0	0	0.02	-
Additional Paid-In Capital	695.94	689.89	179.06	493.31	6.64
Retained Earnings	-693.9	-692.07	-614.65	-394.94	-19.61
Comprehensive Income & Other	-4.58	-4.62	-4.6	-4.56	-
Total Common Equity	-2.53	-6.8	-440.18	93.83	-12.97
Shareholders' Equity	-2.53	-6.8	-139.63	93.83	6.95
Total Liabilities & Equity	388.89	435.02	305.05	165.89	9.67
Total Debt	13.35	13.98	10.96	37.93	1.28
Net Cash (Debt)	146.98	198.63	65.96	96.68	3.46
Net Cash Growth	103.12%	201.15%	-31.78%	2698.18%	-
Net Cash Per Share	5.95	11.44	12.76	19.88	0.91
Filing Date Shares Outstanding	26	25.91	5.4	-	3.81
Total Common Shares Outstanding	26	25.77	5.4	-	3.81
Working Capital	151.14	193.65	22.52	123.06	6.87
Book Value Per Share	-0.10	-0.26	-81.55	-	-
Tangible Book Value	-201.29	-205.57	-638.95	93.83	-12.97
Tangible Book Value Per Share	-7.74	-7.98	-118.38	-	-
Machinery	8.86	8.15	7.63	7.34	0.78
Construction In Progress	2.8	0.7	0.15	0.6	-
Leasehold Improvements	4.15	3.43	0.06	0.06	-

Updated Mar 13, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q